# US 2021/0154286 A1 · Novel Polysaccharide and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0154286 A1
- Document ID: US20210154286A1
- Status: Published application
- Kind: A1
- Application number: 17/165,333
- Filed: 2021-02-02
- Published: 2021-05-27
- Earliest claimed: 2014-02-24
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals S.A.
- Inventors: Michael T. KOWARIK; Michael L. WETTER; Stefan J. KEMMLER; Micha A. HÄUPTLE; Veronica GAMBILLARA; Manuela MALLY
- Web page: https://patentgrep.com/patent/US20210154286A1

## CPC

- A61K 39/0258: {Escherichia}
- A61K 39/02: Bacterial antigens
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/21: from Pseudomonadaceae (F)
- C08B 37/0063: {Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan}
- C08B 37/0066: {Isolation or extraction of proteoglycans from organs}
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/70: {Multivalent vaccine}
- C07K 14/245: Escherichia (G)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

## Claims

### Claim 1

A composition comprising a conjugate of an E. coli O25B antigen covalently coupled to a carrier protein, wherein the E. coli O25B antigen comprises the structure of Formula O25B′:
wherein n is an integer of 1 to 30.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the carrier protein is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli FimH, E. coli FimHC, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin and detoxified variants thereof, C. jejuni AcrA, and C. jejuni natural glycoproteins.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the carrier protein is detoxified EPA or CRM197.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the E. coli O25B antigen is covalently coupled to an Asn residue in the carrier protein.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the Asn residue of the carrier protein is positioned in the consensus sequence Asp(Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro (SEQ ID NO:15).

### Claim 6 (depends on 1)

The composition of claim 1, further comprising a conjugate of an E. coli O1 antigen covalently coupled to a carrier protein, a conjugate of an E. coli O2 antigen covalently coupled to a carrier protein, and a conjugate of an E. coli O6 antigen covalently coupled to a carrier protein.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the E. coli O1 antigen comprises the structure of Formula O1A′:
the E. coli O2 antigen comprises the structure of Formula O2′:
the O6 antigen comprises the structure of Formula O6GlcNAc′:
wherein n is an integer of 1 to 30.

### Claim 8

A composition comprising an E. coli O25B antigen and at least one of the following: (i) an E. coli O1 antigen, (ii) an E. coli O2 antigen, and/or (iii) an E. coli O6 antigen.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the E. coli O25B antigen comprises the structure of Formula O25B′:
wherein n is an integer of 1 to 30.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the E. coli O25B antigen is covalently coupled to a carrier protein.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the carrier protein is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli FimH, E. coli FimHC, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin and detoxified variants thereof, C. jejuni AcrA, and C. jejuni natural glycoproteins.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the carrier protein is detoxified EPA or CRM197.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the E. coli O25B antigen is covalently coupled to an Asn residue in the carrier protein.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the Asn residue of the carrier protein is positioned in the consensus sequence Asp(Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro (SEQ ID NO:15).

### Claim 15 (depends on 8)

The composition of claim 8, wherein the E. coli O1 antigen comprises the structure of Formula O1A′:
the E. coli O2 antigen comprises the structure of Formula O2′:
the O6 antigen comprises the structure of Formula O6GlcNAc′:
wherein n is an integer of 1 to 30.

### Claim 16

A composition comprising (i) an E. coli O25B macromolecule, (ii) an E. coli O1 macromolecule, (iii) an E. coli O2 macromolecule, and (iv) an E. coli O6 macromolecule.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the E. coli O25B macromolecule is conjugated to a carrier protein.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the E. coli O25B macromolecule comprises the structure of Formula O25B′:
wherein n is an integer of 1 to 30.

### Claim 19 (depends on 16)

The composition of claim 16, wherein the E. coli O1 macromolecule is an E. coli O1A macromolecule and the E. coli O6 macromolecule comprises a branching Glc monosaccharide.

### Claim 20 (depends on 16)

The composition of claim 16, wherein each of the E. coli macromolecules is a conjugate comprising a carrier protein.
